Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study

被引：0
|
作者：
Zhang, Yong
Che, Shaomin
Chen, Nanzheng
Li, Xinju
Fu, Junke
Yu, Chenao
Wang, Tianren
Liang, Runjia
Xu, Haozhen
Wu, Qifei
Jia, Zhuoqi
Zhu, Cailin
Gong, Tuotuo
Li, Haijun
Zhang, Boxiang
Hu, Yunyun
Liu, Yaqi
机构：
[1] Xi An Jiao Tong Univ, Dept Thorac Surg, Affiliated Hosp 1, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Radiat Oncol, Affiliated Hosp 1, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16090
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
    Wu, Zhigang
    Zheng, Qiang
    Chen, Haiquan
    Xiang, Jiaqing
    Hu, Hong
    Li, Hang
    Pan, Yunjian
    Peng, Yizhou
    Yao, Xingxin
    Liu, Pengcheng
    Sun, Yihua
    Li, Bin
    Zhang, Yawei
    JOURNAL OF THORACIC DISEASE, 2021, 13 (06) : 3518 - 3528
  • [42] Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study
    Zhang, Renquan
    Song, De Sheng
    Liu, Wei
    Yao, Long
    Chen, An Guo
    Ge, Wei
    Hu, Shao Hui
    Chen, Jian
    Huang, Yun Long
    Xun, Jun Rui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial
    Wu, Wenjie
    Wang, Lin
    Zhang, Tong
    Zhang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Neoadjuvant tislelizumab for resectable recurrent hepatocellular carcinoma: A non-randomized control, phase II trial (TALENT)
    Chen, S.
    Wang, Y.
    Xie, W.
    Shen, S.
    Peng, S.
    Kuang, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S867 - S867
  • [45] Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Sun, Hai-Bo
    Yan, Sen
    Liu, Xian-Ben
    Xing, Wen-Qun
    Chen, Pei-Nan
    Liu, Shi-Lei
    Li, Peng
    Ma, Ya-Xing
    Lerut, Toni
    Daoud, Ahmed
    Jiang, Duo
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (04) : 2443 - 2450
  • [46] A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
    Shen, L.
    Ajani, J. A.
    Kim, S-B.
    Van Cutsem, E.
    Guo, B.
    Song, J.
    Paton, V.
    Kato, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma
    Huang, Bingjiang
    Shi, Haiyan
    Gong, Xiaohua
    Yu, Jing
    Xiao, Caixia
    Zhou, Bin
    Liang, Zibin
    Li, Xiaojian
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (05) : 2013 - 2021
  • [48] Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.
    Yang, Hang
    Zhang, Guoqing
    Li, Xiangnan
    Jiao, Jia
    Guo, Yanan
    Zhang, Yan
    Hou, Zhichao
    Huang, Qi
    Zhao, Jia
    Li, Jindong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 360 - 360
  • [49] Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial
    Lu, Zhihao
    Cao, Yanshuo
    Dai, Liang
    Dong, Fengxiao
    Shen, Lin
    CANCER RESEARCH, 2024, 84 (07)
  • [50] Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
    Qin, Jianjun
    Xue, Liyan
    Hao, Anlin
    Guo, Xiaofeng
    Jiang, Tao
    Ni, Yunfeng
    Liu, Shuoyan
    Chen, Yujie
    Jiang, Hongjing
    Zhang, Chen
    Kang, Mingqiang
    Lin, Jihong
    Li, Hecheng
    Li, Chengqiang
    Tian, Hui
    Li, Lin
    Fu, Junke
    Zhang, Yong
    Ma, Jianqun
    Wang, Xiaoyuan
    Fu, Maoyong
    Yang, Hao
    Yang, Zhaoyang
    Han, Yongtao
    Chen, Longqi
    Tan, Lijie
    Dai, Tianyang
    Liao, Yongde
    Zhang, Weiguo
    Li, Bin
    Chen, Qixun
    Guo, Shiping
    Qi, Yu
    Wei, Li
    Li, Zhigang
    Tian, Ziqiang
    Kang, Xiaozheng
    Zhang, Ruixiang
    Li, Yong
    Wang, Zhen
    Chen, Xiankai
    Hou, Zhiguo
    Zheng, Rongrong
    Zhu, Wenqing
    He, Jie
    Li, Yin
    NATURE MEDICINE, 2024, : 2549 - 2557
12345